Empowering people with diabetes: Improving perceptions and outcomes with technical advances in insulin pens

Postgraduate Medicine

Volumn 124, Issue 5, 2012, Pages 110-120

  Oyer, David ^a   Niemeyer, Marcus ^b   Moses, Alan ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NOVO NORDISK A S   (Denmark)

^c NOVO NORDISK INC   (United States)

Author keywords

Diabetes; Patient outcomes; Quality of life; Refilled insulin pen; Usability; Vial and syringe

Indexed keywords

INSULIN; ANTIDIABETIC AGENT;

ARTICLE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; EQUIPMENT DESIGN; HUMAN; INSULIN TREATMENT; NEEDLE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; SYRINGE; INTRADERMAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, CUTANEOUS; DIABETES MELLITUS; EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT SATISFACTION; QUALITY OF LIFE;

EID: 84873277803     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.09.2587     Document Type: Article

References (88)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-986.
3. Brod M, Kongsø JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18(1):23-32.
4. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.
5. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240-245.
6. Bashoff EC, Beaser RS. Insulin therapy and the reluctant patient. Overcoming obstacles to success. Postgrad Med. 1995;97(2):86-90, 93-96.
7. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(suppl B):S89-S100.
8. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379-1385.
9. Bohannon NJ, Ohannesian JP, Burdan AL, Holcombe JH, Zagar A. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther. 2000;22(9):1049-1067.
10. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848.
11. Mollema ED, Snoek FJ, Adèr HJ, Heine RJ, van der Ploeg HM. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res. 2001;51(5):665-672.
12. Mollema ED, Snoek FJ, Heine RJ, van der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med. 2001;18(8):671-674.
13. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46(3):239-246.
14. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20(3):292-298.
15. Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract. 1995;41(2):169-175.
16. Hirsch LJ, Gibney MA, Albanese J, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm X 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26(6): 1531-1541.
17. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43(1):69-74.
18. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999;22(1): 137-140.
19. Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 1995;28(3):173-177.
20. Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med. 1999;106(5):57-58, 61-64, 68.
21. Chantelau E, Schiffers T, Schütze J, Hansen B. Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns. 1997;30(2):167-173.
22. Kadiri A, Chraibi A, Marouan F, Ababou MR, el Guermai N, Wadjinny A, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract. 1998;41(1):15-23.
23. Albano S; Orbiter Study Group. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. The ORBITER Study Group. Acta Biomed. 2004;75(1):34-39.
24. Lombardo F, Salzano G, Messina MF, De Luca F. Compliance and administration methods in management of type 1 diabetes. Acta Biomed. 2005;76(suppl 3):66-69.
25. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498-1505.
26. Stockl K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin. 2007;23(1):133-146.
27. Fox C, McKinnon C, Wall A, Lawton A. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diabetes Int. 2002;19(4):104-107.
28. Graff MR, McClanahan MA. Assessment by patients with diabetes mel-litus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-496.
29. Sucic M, Galic E, Cabrijan T, et al. Patient acceptance and reliability of new Humulin/Humalog 3.0 mL prefilled insulin pen in ten Croatian diabetes centres. Med Sci Monit. 2002;8(3):PI21-PI26.
30. Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care. 1994;17(8): 874-878.
31. Corsi A, Torre E, Coronel G, et al. Pre-filled insulin pen in newly insulin-treated diabetic patients over 60 years old. Diab Nutr Metab. 1997;10(2):78-81.
32. Shelmet J, Schwartz S, Cappleman J, et al; InnoLet Study Group. Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Res Clin Pract. 2004;63(1):27-35.
33. de Luis DA, Aller R, Cuellar L, et al. Effect on quality of life with a new insulin injection device in elderly patients with diabetes mellitus type 2. J Diabetes Complications. 2004;18(4):216-219.
34. Asamoah E. Insulin pen-the "iPod" for insulin delivery (why pen wins over syringe). J Diabetes Sci Technol. 2008;2(2):292-296.
35. Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35(5):789-798.
36. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-1725; discussion 1710-1711.
37. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-962.
38. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29(spec no):1294-1305.
39. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4(2):165-174.
40. Penfornis A, Horvat K. Dose accuracy comparison between SoloSTAR and FlexPen at three different dose levels. Diabetes Technol Ther. 2008;10(5):359-362.
41. Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin. 2008;24(5): 1429-1434.
42. Pfützner A, Reimer T, Hohberg C, Frøkjaer LP, Jørgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545-2549.
43. Weise A, Pfützner JW, Borig J, et al. Comparison of the dose accuracy of prefilled insulin pens. J Diabetes Sci Technol. 2009;3(1): 149-153.
44. Hänel H, Weise A, Sun W, Pfützner JW, Thomé N, Pfützner A. Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol. 2008;2(3):478-481.
45. Ignaut DA, Opincar MR, Clark PE, Palaisa MK, Lenox SM. Engineering study comparing injection force and dose accuracy between two prefilled insulin injection pens. Curr Med Res Opin. 2009;25(12): 2829-2833.
46. Krzywon M, Abdel-Tawab M, van der Burg T, Fuhr U, Schubert-Zsilavecz M. Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin. 2010;26(4):901-905.
47. Krzywon M, van der Burg T, Fuhr U, Schubert-Zsilavecz M, Abdel-Tawab M. Study on the dosing accuracy of commonly used disposable insulin pens. Diabetes Technol Ther. 2012;14(9):804-809.
48. Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. FlexTouch: a prefilled insulin pen with a novel injection mechanism with consistent, high accuracy at low- (1 U), medium-(40 U), and high- (80 U) dose settings. J Diabetes Sci Technol. 2011;5(5):1195-1199.
49. Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. An assessment of dose accuracy and injection force of a novel prefilled insulin pen: comparison with a widely used prefilled insulin pen. Expert Opin Drug Deliv. 2011;8(10):1271-1276.
50. Hermanns N, Kulzer B, Haak T. Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting. Diabetes Technol Ther. 2008;10(4):322-327.
51. Friedrichs A. Dose accuracy of SoloSTAR and FlexPen as assessed in a clinical setting. Diabetes Technol Ther. 2009;11(9):609-613.
52. Hemmingsen H, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens. Diabetes Technol Ther. 2011;13(12):1207-1211.
53. Lefkowitz M. Do different body colors and labels of insulin pens enhance a patient's ability to correctly identify pens for injecting long-acting versus short-acting insulins? J Diabetes Sci Technol. 2011;5(1):136-149.
54. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12(suppl 1):S101-S108.
55. Campos C, Lajara R, Deluzio T. Usability and preference assessment of a new prefilled insulin pen versus vial and syringe in people with diabetes, physicians and nurses. Expert Opin Pharmacother. 2012;13(13):1837-1846.
56. Hancu N, Czupryniak L, Genestin E, Sourij H. A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. J Diabetes Sci Technol. 2011;5(5):1224-1234.
57. Fischer JS, Edelman SV Schwartz SL. United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens. J Diabetes Sci Technol. 2008;2(6):1157-1160.
58. Clark PE, Valentine V, Bodie JN, Sarwat S. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens. Curr Med Res Opin. 2010;26(7):1745-1753.
59. Garg S, Bailey T, DeLuzio T, Pollom D. Preference for a new prefilled insulin pen compared with the original pen. Curr Med Res Opin. 2011; 27(12):2323-2333.
60. Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau DA. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011;8(10):1259-1269.
61. Bailey T, Thurman J, Niemeyer M, Schmeisl G. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin. 2011;27(10):2043-2052.
62. Nadeau DA, Campos C, Niemeyer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012;28(1):3-13.
63. Carter J, Beilin J, Morton A, De Luise M. Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia. J Diabetes Sci Technol. 2009;3(6):1425-1438.
64. Sommavilla B, Jørgensen C, Jensen KH. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2223-2232.
65. Arslanoǧlu I, Saka N, Bundak R, Günöz H, Darendeliler F. A comparison of the use of premixed insulins in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM. Is there a decreased risk of night hypoglycemia? J Pediatr Endocrinol Metab. 2000;13(3):313-318.
66. Berger AS, Saurbrey N, Kühl C, Villumsen J. Clinical experience with a new device that will simplify insulin injections. Diabetes Care. 1985;8(1):73-76.
67. Hanas R, Ludvigsson J. Experience of pain from insulin injections and needle-phobia in young patients with IDDM. Pract Diabetes Int. 1997;14(4):95-99.
68. Kølendorf K, Beck-Nielsen H, Oxenbøll B. Clinical experience with NovoPen II and insulin Protaphane HM Penfill. Postgrad Med J. 1988;64(suppl 3):14-16; discussion 21.
69. Joslin Diabetes Center website. Writing prescriptions for monitors, insulin, syringes, pens and pen needles. http://www.bd.com/us/diabetes/ hcp/main.aspx?cat=3065&id=63268. Accessed August 8, 2012.
70. Egekvist H, Bjerring P, Arendt-Nielsen L. Pain and mechanical injury of human skin following needle insertions. Eur J Pain. 1999;3(1): 41-49.
71. Siegmund T, Blankenfeld H, Schumm-Draeger PM. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: "thin-wall" needles compared to "regular-wall" needles: an open-label study. Diabetes Technol Ther. 2009;11(8):523-528.
72. Hirsch L, Gibney M, Berube J, Manocchio J. Impact of a modified needle tip geometry on penetration force as well as acceptability, preference, and perceived pain in subjects with diabetes. J Diabetes Sci Technol. 2012;6(2):328-335.
73. Hofman P, Lilleøre SK, Ter-Borch G. Needle with a novel attachment versus conventional screw-thread needles: a preference and ease of use test among children and adolescents with diabetes. J Diabetes Sci Technol. 2011;5(6):1480-1487.
74. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8): 529-538.
75. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/ soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27(10):2495-2497.
76. Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347-1357.
77. Lajara R, Guerrero G, Thurman J. Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe [published online ahead of print September 13, 2012]. Expert Opin Drug Deliv.
78. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689.
79. Lee IT, Liu HC, Liau YJ, Lee WJ, Huang CN, Sheu WH. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract. 2009;15(4):699-703.
80. Nicolucci A, Cucinotta D, Squatrito S, et al; QuoLITy Study Group. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovas Dis. 2009;19(1):45-53.
81. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31(3):430-432.
82. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-824.
83. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45(6):1115-1121.
84. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120(1):1-34.
85. Pfützner A, Musholt PB, Schipper C, et al. Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2012;28(1):15-21.
86. Schipper C, Musholt P, Niemeyer M, et al. Patient device assessment evaluation of two insulin injection devices in a mixed cohort of insulin-treated patients with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2012;28(8):1297-1303.
87. Hansen B, Lilleøre SK, Ter-Borch G. Needle with a novel attachment versus conventional screw-thread needles: a preference and usability test among adults with diabetes and impaired manual dexterity. Diabetes Technol Ther. 2011;13(5):579-585.
88. van der Burg T. Injection force of SoloSTAR® compared with other disposable insulin pen devices at constant volume flow rates. J Diabetes Sci Technol. 2011;5(1):150-155.